Holen Sie sich die Stockscreener-App
9.42
2.61%
0.24
Schlusskurs vom Vortag:
$9.18
Offen:
$9.45
24-Stunden-Volumen:
12,261
Relative Volume:
0.24
Marktkapitalisierung:
$200.18M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.50M
KGV:
-5.1964
EPS:
-1.8128
Netto-Cashflow:
$-25.87M
1W Leistung:
+4.09%
1M Leistung:
-6.08%
6M Leistung:
-19.14%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.27
$9.72
1-Wochen-Bereich:
$8.91
$9.72
52-Wochen-Spanne:
$5.44
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Firmenname
Satellos Bioscience Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare MSLE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
9.435 | 194.77M | 0 | -28.50M | -25.87M | -1.8128 |
VRTX
Vertex Pharmaceuticals Inc
|
521.01 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.50 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.98 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.18 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.52 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-06 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Aktie (MSLE) Neueste Nachrichten
Satellos Bioscience is facing clinical execution risks—can it regain investor confidence and turn sentiment around? - kalkine.ca
Satellos assigns INN forazapadin to DMD drug candidate By Investing.com - Investing.com Canada
A muscle disease treatment candidate gets a new global name: forazapadin - Stock Titan
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Did Satellos Bioscience (TSX:MSCL) Surge 7.43% on 31 August 2026? - kalkine.ca
Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences - TipRanks
Satellos cash runway through 2027, Phase 2 DMD | MSLE SEC FilingForm 6-K - Stock Titan
Satellos to Participate in Upcoming Investor Conferences - Stock Titan
Satellos Bioscience (TSX:MSCL) Rises 7.43% as Duchenne Clinical Progress and Upcoming Data Catalysts Lift Investor Optimism - kalkine.ca
Satellos Bioscience Stock Falls 7.42% as Clinical-Stage Risk and Development Uncertainty Pressure Sentiment - kalkine.ca
Satellos Bioscience Inc. (TSX:MSCL) Falls 7.42% as Biotech Volatility and Clinical Development Risks Pressure Investor Confidence - kalkine.ca
LifeSci Capital Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Satellos Bioscience (MSLE) Slides Nearly 10% in High-Volume Biotech SelloffCalendar Spread Trade - vinanet.vn
Empery Asset Management LP Sells 123,000 Shares of Satellos Bioscience Inc. $MSLE - MarketBeat
LifeSci Capital Initiates Satellos Bioscience(MSLE.US) With Buy Rating, Announces Target Price $22 - Moomoo
Satellos Bioscience Stock Under Pressure as Biotech Volatility Raises Correction Risk - kalkine.ca
Satellos (MSLE) Stock: Ends Higher by 0.59% at $10.15 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest ReadingMonthly Profile - vinanet.vn
DMD Biotech Delivers Early Muscle Data as SAT-3247 Advances - Streetwise Reports
Why Satellos Bioscience Inc. stock is gaining today - wealthawesome.com
Satellos Bioscience (MSLE) Institutional Ownership 2026 - MarketBeat
Satellos Bioscience Stock Drops 3.39% as Investors Weigh Duchenne Muscular Dystrophy Therapy, Clinical Development and Biotech Risk - kalkine.ca
Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
HC Wainwright Reaffirms Buy Rating for Satellos Bioscience (NASDAQ:MSLE) - MarketBeat
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Satellos Bioscience Inc. MSCL Earnings Miss Estimates by 37.0% - Wealth Awesome
Satellos TRAILHEAD Data Suggests Muscle Regeneration as Company Cash Reaches US$61.8M - Streetwise Reports
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility - TipRanks
Satellos Bioscience (MSLE) enters $50M at-the-market share deal - Stock Titan
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.78, Implies 122% Upside - TradingView
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
Satellos Bioscience Inc. Stock 12‑Month Price Target Cut to $21.92, Implies 123% Upside - TradingView
Oppenheimer Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos reports improved muscle composition in TRAILHEAD study - scanx.trade
Satellos Bioscience: Q2 Earnings Snapshot - aol.com
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base - TipRanks
Satellos Q2 loss widens to $11.7M, EPS misses estimates - scanx.trade
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress - The Manila Times
Satellos Bioscience (NASDAQ: MSLE) ramps Duchenne R&D and strengthens cash - Stock Titan
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Satellos Bioscience Files For Mixed Shelf Of Up To $300 Million - TradingView
Satellos Bioscience (MSLE) sets up US$300M shelf to fund Duchenne drug - Stock Titan
Satellos Bioscience (MSLE) Holds Ground Near $10.01 as Key Support Level Comes into FocusInitial Balance - dars.gov.et
Satellos Bioscience Inc. (TSX:MSCL) Stock Declines as Biotech Risks and Funding Concerns Pressure Sentiment - kalkine.ca
Satellos Bioscience (TSX:MSCL): Can This Toronto Biotech Actually Regrow Muscle in Duchenne Patients? - kalkine.ca
Satellos Bioscience Stock Climbs as Duchenne Therapy Data Strengthen Bullish Momentum: Can TSX:MSCL Extend Its Recovery? - kalkine.ca
Satellos Wins FDA Fast Track for SAT-3247 as Its Duchenne Programme Enters a Catalyst-Rich Second Half - kalkine.ca
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
Satellos Bioscience Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Satellos Bioscience Inc. (TSX:MSCL) Faces Crucial Smallcap Tests - Kalkine Media
Finanzdaten der Satellos Bioscience Inc-Aktie (MSLE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):